Actualités

Innate Pharma

Publiée le 08/02/2007

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, announced today that IPH 2101 (NN 1975), a fully human monoclonal antibody developed by Novo Nordisk A/S in collaboration with Innate Pharma, was administered for the first time in humans (in January 2007), as part of a Phase I clinical trial for patients with acute myeloid leukemia (“AML”).

The trial is being performed at two of the largest cancer clinical research centers in France, the Institut Paoli-Calmettes in Marseille and the Institut Gustave-Roussy in Paris.

Innate Pharma received an undisclosed payment for this first clinical trial milestone.

2007

Découvrez le site Sofinnova Ventures, notre société soeur a San Francisco http://www.sofinnova.com